87 results about "Neutrophile" patented technology

The invention provides a biomarker for diagnosing systemic lupus erythematosus and application of the biomarker. According to the application disclosed by the invention, the expression of Ferritin in neutrophil of a systemic lupus erythematosus patient is found to be obviously reduced and is improved after treatment, the neutrophil has disease specificity and cell specificity, and the Ferritin in the neutrophil has important significance on clinical diagnosis or auxiliary diagnosis of systemic lupus erythematosus and disease condition evaluation.

The features of the present invention for providing a novel neutrophil activator are as follows. 1. An IL-8 production accelerator containing at least one selected from GlcCer[d18:2(4E,8Z) / 18:0], GlcCer[d18:2(4E,8Z) / 20:0], GlcCer[d18:2(4E,8Z) / 22:0], GlcCer[d18:2(4E,8Z) / 24:0], and GlcCer[d18:2(4E,8Z) / 26:0] as an active ingredient. 2. An IL-8 production accelerator containing GlcCer[d18:2(4E,8E) / 24:0] as an active ingredient. 3. An IL-8 production accelerator containing at least one selected from GlcCer[t18:1(8Z) / 24:0] and GlcCer[t18:1(8Z) / 26:0] as an active ingredient. 4. An IL-8 production accelerator containing GlcCer[d18:1(4E) / 20:0] as an active ingredient. 5. An IL-8 production accelerator containing at least one selected from Cer(t18:0 / 22:0), Cer(t18:0 / 23:0), Cer(t18:0 / 24:0), Cer(t18:0 / 25:0), and Cer(t18:0 / 26:0) as an active ingredient. 6. An IL-8 production accelerator containing at least one selected from Cer[t18:1(8Z) / 24:0] and Cer[d18:2(4E,8Z) / 20:0] as an active ingredient. 7. An IL-8 production accelerator containing at least one selected from Oryza Ceramide A, Oryza Ceramide B, and Oryza Ceramide C as an active ingredient.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The application belongs to the technical field of medicine, and specifically discloses a kind of nasal spray composition and nasal spray and application, the nasal spray composition includes the following components: hyaluronic acid, trehalose, N-acetyl-L-cysteine, methylene succinic acid, gallic acid, taurine, coenzyme Q10, rosemary essential oil.The nasal spray composition provided by the application is accurately adjusted, can give full play to the advantages of each component, provide better nasal ventilation and humidity.The nasal spray composition provided by the application can inhibit the excessive activation of LPS-induced neutrophil Netosis in vitro culture and the excessive activation of LPS-induced mouse airway neutrophil Netosis, thereby reducing the inflammatory response in the nasal cavity.

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention relates to the technical field of biological medicine preparations, in particular to application of targeted nanoparticles in treatment of osteoporosis. The targeted nano-particles CL-NPs (at) NEs are developed, CL can stimulate lipolysis of bone marrow adipocytes, osteogenic differentiation is promoted, and therefore the bone marrow microenvironment is improved; meanwhile, autologous neutrophil is used as a carrier to transport CL-NPs, bone marrow fat cells beta3AR are accurately targeted, and the osteoporosis microenvironment can be further improved. Experiments prove that CL-NPs (at) NEs stimulate a bone marrow fat cell beta3 adrenoceptor in a targeted manner, can effectively improve OP, has safety and has the potential to become a novel medicine for osteoporosis.

The invention discloses a novel nuclear magnetic resonance contrast agent Gd-DOTA-PP for targeting citrullinated histone to achieve neutrophil extracellular trap net imaging and a preparation method and application thereof.The method comprises the steps that citrullinated histone targeting polypeptide PP and ligand molecules DOTA-NHS are combined, and a compound DOTA-PP is obtained; and then gadolinium (Gd) ions are introduced into the DOTA-PP through a coordination reaction, and the novel contrast agent Gd-DOTA-PP is prepared. The contrast agent can be selectively combined with an important marker, namely citrullinated histone, of neutrophil extracellular trapping nets (NETs), and T1 weighted imaging signals of a target area are remarkably enhanced. The preparation method is simple and convenient to operate, the preparation process is highly controllable, and the obtained contrast agent has excellent biocompatibility and targeting characteristic. The accurate targeting ability of the probe enables the influence signal of the probe in NETs enrichment areas such as tumor early metastasis, tumor infiltration lymph nodes and the like to be obviously enhanced, a powerful tool is provided for tumor diagnosis, especially accurate diagnosis of the early metastasis, and the probe has important clinical application value.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The invention provides methods of determining the neutrophil level in a sample by determining the level of CD16b, including the intracellular form of CD16b in a sample, such as a blood sample. The methods may further comprise the determination of lactate levels Also provided are associated diagnostic and therapeutic methods. Further provided are kits and devices for performing the methods, particularly lateral flow kits and devices.

Provided in the present invention is a method for preparing a drug-loaded neutrophil. The method comprises the step of co-incubating, in a buffer containing nicotinamide, Q-VD-Oph and vitamin C, a neutrophil and a drug to be loaded. Further provided in the present invention are a drug-loaded neutrophil prepared using the method, and the use of the neutrophil in the preparation of a drug. The method provided in the present invention can significantly reduce the apoptosis ratio of neutrophils, reduce the in-vitro activation level of neutrophils, improve neutrophil viability and chemotactic efficiency under inflammatory conditions, and also improve the drug-loading efficiency of neutrophils, thereby realizing the efficient release of a drug at a disease site, and further improving the in-vivo survival time and efficacy of the drug.

This invention discloses an engineered attenuated Salmonella VNP-SNase, its preparation method, and its applications, including methods and compositions for treating various solid tumors or metastatic tumors. Specifically, engineered attenuated Salmonella capable of expressing and secreting SNase is recruited to the tumor microenvironment through tumor targeting, specifically degrading intratumoral neutrophil extracellular traps (NETs), weakening the killing effect of NETs on Salmonella, increasing its intratumoral colonization, and simultaneously improving the tumor-promoting and immunosuppressive effects caused by NETs, ​​while effectively preventing bacteria from off-target into normal organs. By releasing SNase to activate / regulate the immune system and directly / indirectly inhibit tumors, it can act as an effective immune effector.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The invention provides a neutrophil transporter, a marker CD66b of the neutrophil transporter, and application of combination of the CD66b and other indexes to early diagnosis or auxiliary diagnosis of blood coagulation disorder. The invention provides CD66b, application of CD66b and other index combinations to preparation of reagents or kits for early diagnosis or auxiliary diagnosis of blood coagulation disorders, related reagents and kits, and a system for early diagnosis or auxiliary diagnosis of blood coagulation disorders. The CD66b, the combination of the CD66b and other indexes, the reagent or the kit and the system provided by the invention have the effect of early diagnosis or auxiliary diagnosis of the blood coagulation disorder.

The present application relates to the technical field of plant extract, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, wherein the plant extract composition comprises mulberry leaf extract, white kidney bean extract and balsam pear powder with a mass ratio of 8:(1-24):(1-64). The present application optimizes the mass ratio of the mulberry leaf extract, the white kidney bean extract and the balsam pear powder, so that the plant extract with the mulberry leaf extract, the white kidney bean extract and the balsam pear powder as main raw materials has a significantly better effect on reducing blood sugar than the plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of peripheral nerve neutrophils, improving peripheral nerve inflammation, synergistically enhancing the fluorescence intensity of peripheral nerves, improving peripheral nerve injury, and inhibiting the enzyme activity of bacteria-derived dipeptidyl peptidase-4.

The invention discloses an application of Osmunda japonica in relieving fish food-borne intestinal inflammation, regulating intestinal flora and inhibiting bacteria, based on a 9-day soybean meal induced zebra fish enteritis model, 2% o of Osmunda japonica is added, so that aggregation of neutrophils and macrophages in middle and posterior intestines can be relieved, and zebra fish food-borne intestinal inflammation can be relieved; meanwhile, by means of intestinal flora sequencing, it is found that by adding 2% o of rhizoma osmundae, the intestinal flora of the fish with the food-borne intestinal inflammation can be improved; the result of an aeromonas hydrophila in-vitro bacteriostasis experiment shows that the rhizoma osmundae aqueous extract has a remarkable effect of inhibiting aeromonas hydrophila, has an inhibition zone and has a certain bacteriostasis effect, and a zebra fish in-vitro challenge experiment shows that the survival rate of zebra fish can be increased by adding 2 per thousand of rhizoma osmundae.

The invention discloses bifidobacterium adolescentis BAS05 and application thereof in preparation of a medicine for preventing or treating intestinal inflammation, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium adolescentis BAS05 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 22515. The bifidobacterium adolescentis BAS05 can inhibit DSS from inducing neutrophil to gather towards the intestinal tract of the zebra fish, so that a theoretical reference and a guidance basis are provided for developing a medicine for preventing or treating intestinal inflammation by utilizing the bifidobacterium adolescentis BAS05.

The invention discloses a hyperlipidemia risk prediction model and a risk prediction system during treatment of TSC by SRL, and belongs to the field of disease model prediction. According to the hyperlipemia risk prediction model disclosed by the invention, three parameters including SRL (Sirolimus) blood drug valley concentration, baseline triglyceride and neutrophil count of an object to be evaluated are input; the output is the risk probability of the to-be-evaluated object suffering from hyperlipemia; large sample data is adopted to train a model, cases suffering from hyperlipemia are positive samples, other cases are negative samples, and the model is selected from XGBoost, a support vector machine, a random forest, a decision tree and LightGBM. The key risk factors of hyperlipemia after SRL treatment are disclosed, accurate prediction of the risk of SRL-related hyperlipemia is achieved, especially the RO-AUC of the XGBoost model reaches 0.95, and the method can be applied to detection instruments, monitoring networks, wearable devices and other scenes.

The application discloses a kind of nanomedicine for treating sepsis and its preparation method and purposes, belong to medical technology field.The nanomedicine is tetrahedral framework nucleic acid modified by N-acetyl proline-glycine-proline.The nanomedicine of the application can be transported to inflammatory site by following the chemotaxis of neutrophil to inflammatory site, to play the target regulation effect on sepsis, to increase the bioavailability of drug, improve the target treatment effect of drug.The nanomedicine of the application can be used not only for preparing the drug for treating sepsis, but also for preparing the drug for treating other diseases caused by neutrophil infiltration, and has wide application prospect.

The invention discloses a method for inducing HL-60 cells to generate a neutrophil extracellular trap net and application of the method. The method comprises the following steps: firstly, inducing and differentiating HL-60 cells into neutrophile granulocyte-like cells by using dimethyl sulfoxide (DMSO), and then stimulating the differentiated cells by using phorbol ester (PMA), thereby inducing to form the neutrophile granulocyte extracellular trapping net. Preferably, the final concentration of the DMSO is 0.8%-1.5%, the final concentration of the PMA is 50-400 nM, and the stimulation time is 2-4 hours. According to the invention, a polylysine-coated substrate is adopted to enhance the structural stability of NETs, and SYTOX Green nucleic acid dye is adopted for fluorescence detection. According to the invention, a complete and standardized experimental system formed from the HL-60 cell to the NETs is successfully established, the technical problems of unstable primary cell source and poor experimental repeatability are overcome, the operation is simple and convenient, the result is reliable, and an ideal tool is provided for related research of the NETs.

The invention relates to application of neutrophil subpopulation in pathogen infection detection. Specifically, the invention relates to an application of a protein, a polypeptide or a fragment thereof in detecting pathogen infection of a mammalian sample, and the protein, the polypeptide or the fragment thereof can be specifically combined with CD54, CD14 or a combination of CD54 and CD14; wherein the CD54 and the CD14 are proteins which are coupled with the neutrophil. The detection kit and the detection method provided by the invention are simple to operate, the detection sensitivity and specificity are far higher than those of CRP detection results, and early and rapid judgment can be made on infection-related diseases.

The invention provides an irinotecan hydrochloride lipidosome composition. The irinotecan hydrochloride lipidosome composition is prepared from the following components in a specific weight ratio: irinotecan hydrochloride, hydrogenated soybean phospholipid, cholesterol and mPEG2000-DSPE. The invention also provides a preparation method of the liposome composition. The liposome disclosed by the invention can be used for remarkably reducing the serious hematotoxicity of irinotecan hydrochloride, and particularly remarkably reducing the occurrence rate of neutropenia.

The invention discloses synthesis and application of an elastin fluorescent probe for early diagnosis of diabetic complications, and belongs to the technical field of biological detection. According to the invention, the neutrophil elastin specific fluorescent probe NanoNEP is constructed, and the NanoNEP is used for the first time to successfully visualize and quantify the NE activity in diabetes wound healing. The invention also verifies the effect of in-vivo NE imaging in an animal model, and NanoNEP is used for monitoring the activity of NE in serum and skin tissue of a diabetic individual. The fluorescent probe NanoNEP prepared by the invention can be used as an important tool for early diagnosis of diabetic complications, and has a huge application prospect in the technical fields of medical detection, diagnosis and the like.

The present disclosure discloses a data acquisition and analysis method based on diabetes data analysis and processing equipment, and relates to the field of diabetes data analysis and prediction. The equipment includes a computer, a placement rack and a flow cytometer. The mitochondrial membrane potential data in the neutrophil is performed independent evaluation and analysis. If the proportion of cells with increased mitochondrial membrane potential are in the neutrophil is greater than 70%, the person is at the risk of diabetes, otherwise the risk is lower, so that the subsequent development of diabetes in a person with normal blood glucose can be predicted, and the diabetes can be prevented in advance.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The application belongs to the technical field of protein detection, and particularly relates to a protein marker detection platform based on a DNA nanoflower cascade CRISPR system and a construction method and application thereof. The protein marker detection platform based on the DNA nanoflower cascade CRISPR system comprises an upstream module of protein marker input signal amplification based on a DNA nanoflower and a downstream module of output signal amplification based on a CRISPR / Cas system. When the detection platform is used for protein marker detection, the upstream module based on the DNA nanoflower can convert the protein marker into hundreds or thousands of DNA signals, the DNA signals are recognized and activated by a Cas-crRNA compound to have Cas protein cis and trans cleavage activity, so that the output signal is amplified, high sensitivity and rapid detection of the protein marker are achieved, and in particular in detection of a neutrophil gelatinase lipocalin marker in a kidney injury disease, the detection limit is 500 fg / ml.

The present disclosure relates to methods of identifying a subject likely to respond to treatment with a myeloperoxidase (MPO) inhibitor based on neutrophil levels and / or a concentration of at least one protein biomarker in the subject. The disclosure also relates to methods of selecting a subject for MPO inhibitor treatment, methods of predicting whether a subject will respond to MPO inhibitor treatment, and methods of treating a subject likely to respond to MPO inhibitor treatment. The present disclosure also relates to a method of predicting an improved clinical response in a subject having an MPO-related disorder following treatment with an MPO inhibitor.

The present application relates to the field of biological medicine technology, and relates to a kind of oral squamous cell carcinoma related marker and drug screening method. By 5R 16S rRNA-seq analysis and representative fluorescence in situ hybridization technique verification, the abundance of Capnocytophaga leadbetteri (C. leadbetteri) in oral squamous cell carcinoma (Oral Squamous Cell Carcinoma, OSCC) tissue is significantly higher than that in normal tissue, and it can be used as the diagnostic marker of OSCC. The present application further clarifies the specific molecular mechanism of the bacteria promoting tumor progression, excludes environmental microbial interference through aseptic mouse model, and directly proves that C. leadbetteri single bacterial colonization can induce oral epithelial hyperplasia and barrier damage. Experiments confirm that the bacteria up-regulate chemotactic factors by activating TLR4 / MyD88 / NF-κB signaling axis, recruit neutrophils to form pro-tumor immune microenvironment. In vivo animal model confirms that after using BAY 11-7082 to inhibit NF-κB or using anti-Ly6G antibody to eliminate neutrophils, the tumor volume and weight are significantly reduced (P<0.01), and the present application provides a new treatment target and drug screening theoretical basis for OSCC.

The present invention relates to a pharmaceutical composition comprising a protein complex, and its pharmaceutical applications for treating or preventing conditions characterized by impaired leukocyte production, such as neutropenia. The protein complex can also be formed by linking an immunoglobulin Fc region to a bioactive polypeptide via a non-peptide polymer linked to the immunoglobulin Fc region. [Solution] The present invention provides a method for treating chemotherapy-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient, and a method for treating radiation-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient.